Phase 3Completed
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis
- Sponsor
- Teva Pharmaceuticals USA (Industry)
- Enrolment
- 332 enrolled
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- TVB-009; Prolia®
- Ages
- adults, older adults
- Registry
- NCT04729621
From the registry
The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)
Primary outcomes
- Percent Change From Baseline in LS-BMD at Week 52